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N-Heterocyclic carbene boron trifluoride (NHC-BF3) conjugates were successfully radiofluorinated by
SnCl4-promoted
18F–19F isotopic exchange reaction in one labelling step. This method afforded in vivo
stable PET agents that efficiently bound to targeted tumours yielding PET images with good tumour-to-
background contrast.Fluorine-18 is typically incorporated into molecular tracers at
the last step of the overall synthesis process due to its short half-
life (110 minutes). One of the recent methods for late-stage
radiouorination is a pre-functionalization approach in which
a 18F-captor such as a BF3 or a BF2 unit is preinstalled into
bioactive molecules.1 Several examples, including the radio-
uorinations of alkylammoniomethyltriuoroborate2 (AMBF3)
(Scheme 1A), BODIPY3 (Scheme 1B) and phosphonium aryltri-
uoroborate4 (PArBF3) (Scheme 1C) conjugates, were
demonstrated.late-stage radiofluorinations of
previous reports (A–C) and this
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EC), National Science and Technology
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tion (ESI) available. See DOI:
o this work.In the case of AmBF3 and PArBF3 conjugates, the
18F–19F
isotopic exchange of the BF3 moiety could be simply processed
in acidic aqueous media.2d,4,5 However, the 18F–19F isotopic
exchange of the BF2 unit in BODIPY conjugates could only be
efficiently done in a dried organic solvent with strong Lewis/
BrØnsted acid promotors (SnCl4, SnCl2, or TfOH).3,6
Recently, we demonstrated that the [18F]-maleimide func-
tionalized NHC-BF3 ([
18F]1) (Fig. 1) could be prepared via SnCl4-
promoted 18F–19F isotopic exchange and it could be easily
conjugated to Cys-Phe dipeptide.7 However, the 18F direct
labelling of the NHC-BF3 pre-functionalized bioactive molecule
(Scheme 1D) has not been reported. With this in mind, we
decided to validate the late-stage radiouorination in NHC-BF3
conjugated bioactive molecules, including glutamate–urea–
lysine (2), cyclic RGD-containing peptide (3), and neurotensin
(NT) peptide (4) (Fig. 1). The results on radiosynthesis and PET
imaging of these [18F]-NHC-BF3 conjugates are presented in this
report.
As a starting point, NHC-BF3 conjugated glutamate–urea–
lysine (5), cyclic RGD-containing peptide (6), and neurotensinFig. 1 Chemical structures of maleimide functionalized NHC-BF3
adduct (1) and thiol containing bioactive molecules (glutamate–urea–
lysine (2), cyclic RGD-containing peptide (3) and neurotensin peptide
(4)) studied in this work.
This journal is © The Royal Society of Chemistry 2017
Fig. 2 Radio HPLC profile of the [18F]5 (A), [18F]6 (C) and [18F]7 (D)
obtained after passing through Sep-Pak alumina N cartridge and UV

































































































View Article Onlinepeptide (7) were prepared by thiol-Michael addition click reac-
tion of 1 with 2, 3, and 4, respectively (Scheme 2). This reaction
was performed by mixing the solution of 1 in MeCN with the
solution of 2, 3, or 4 in phosphate buffer solution (PBS) pH 7.5.
The reaction mixture was then incubated at room temperature
for 2 hours before purifying with high-performance liquid
chromatography (HPLC). The detection of the molecular ions by
positive-mode electrospray mass spectrometry at m/z 653.1999
for 5, 953.3689 for 6 and 1332.6725 for 7 conrmed the identity
of the conjugates.
Next, we labelled our new NHC-BF3 conjugates by SnCl4-
promoted 18F–19F isotopic exchange reaction. The solution of
NHC-BF3 conjugates and tin(IV)chloride (excess) in anhydrous
MeCN was mixed with azeotropically dried tetrabutylammo-
nium [18F]-uoride (TBAF) (Scheme 2). The mixture was heated
at 70 C for 10 min, then quenched with 1 mL of water and
passed through a Sep-Pak light alumina N cartridge to remove
an unreacted 18F-uoride.
The radio-HPLC proles of [18F]5, [18F]6 and [18F]7 obtained
aer passing through Sep-Pak alumina N cartridge are shown in
Fig. 2A, C and D, respectively. The identity of [18F]-NHC-BF3
conjugates was conrmed by the comparison of their retention
times with those of reference compounds as shown in Fig. 2A
and B in the case of [18F]5. The UV HPLC proles of 6 and 7 are
displayed in the ESI.† The radio-HPLC proles revealed that the
[18F]5, [18F]6 and [18F]7 were obtained as a major product. The
small radio-HPLC peaks of the impurities were also detected,
which could be the results from decomposition due to exposure
to SnCl4. Although the HPLC purication is required, the radi-
olabelling time can be reasonably shortened compared with our
previous report7 as the radio-bioconjugation step between [18F]-
1 and the bioactive molecule is removed.
The decay-corrected radiochemical yield, and specic
activity for [18F]5, [18F]6 and [18F]7 are shown in Table 1. The
radiochemical yields ranging from 21.4 to 29.6% are compa-
rable with those obtained from SnCl4-promoted radiolabelling
of BODIPY-RGD conjugate3a and slightly lower than SnCl2 or
TfOH-promoted radiolabelling of BODIPY conjugates reported
in previous publications.3 The specic activities of all [18F]-Scheme 2 Scheme showing the synthesis and the radiolabelling of 5,
6, and 7.
This journal is © The Royal Society of Chemistry 2017NHC-BF3 conjugates are considerably higher than that of [
18F]-
NHC-BF3-Cys-Phe prepared by two-step radiosynthesis.7
In term of the in vitro stability, [18F]5, [18F]6 and [18F]7
demonstrated negligible decomposition at both 60 and 120 min
aer incubation in phosphate buffer solution pH 7.5 under
ambient temperature (Fig. 3 and ESI†). These results are
consistent with the extremely long hydrolysis half-life of 1
observed by 19F NMR spectroscopy and the in vitro stability
studies of [18F]-NHC-BF3-Cys-Phe shown in the previous report.7
Next, we chose [18F]5, the prostate-specic membrane antigen
(PSMA)-based radiotracer, to perform the in vivo stability study
in mice.
The microPET/CT images obtained at 0.5 h and 4 h post
injection revealed that [18F]5 mainly localized in kidneys due to
its hydrophilic nature (Fig. 4), as seen with other PSMA-based
radiotracers.8 The high accumulation of [18F]5 in kidneys is
partially due to high expression of PSMA within proximal renal
tubules.9 Based on PET quantication, the kidney uptake of
[18F]5 was determined to be 12.1 and 2.3% ID per g at 0.5 h and
4 h post injection, respectively. This nding indicated that [18F]
5 was slowly cleared from kidneys. Additionally, we did not
observe any bone uptake signal due to tracer decomposition
even at 4 h post injection which is similar to the in vivo stability
of the [18F]-NHC-BF3-Cys-Phe.7
In order to validate whether these agents could be used for
cancer imaging, the glioblastoma (U87MG) and pancreatic
(PANC1) tumour bearing mice were injected with the radio-
labelled RGD and NT conjugates, respectively. As shown in
Fig. 5A–C, [18F]6 and [18F]7 nicely visualized tumour in a good
contrast and showed negligible uptake in bone. Additionally,
both tracers barely localized in liver due to the hydrophilic
nature of the NHC-BF3 conjugates which is different from the
bio-distributions of the [18F]-BODIPY-peptide conjugates3a,6a
and the [18F]-ortho-(Ph2MeP)C6H4(BF3)-indomethacin conju-
gate.4 The target specicity of [18F]7 was conrmed by blocking
experiment in which the radiotracer was co-injected with an
excess amount (200 mg) of NT peptide (4). In this blocking
experiment, the tumour uptake of [18F]7 was remarkably
inhibited by nonradioactive NT peptide, conrming theRSC Adv., 2017, 7, 17748–17751 | 17749
Table 1 Radiosynthetic results for [18F]5, [18F]6 and [18F]7
Entry Cpd
Amount
SnCl4 (mL) Temp. (C) RCY
a (%) SAb (GBq mmol1)mg mmol
1 [18F]5 200 0.31 1 70 29.6 6.0
2 [18F]6 300 0.32 1 70 25.6 3.5
3 [18F]7 400 0.30 1 70 21.4 3.4
a Radiochemical yields (RCY) were calculated by dividing the 18F-activity of the isolated product by the starting 18F activity. b Specic activities (SA)
were determined by dividing the isolated product activity by the amount of the product (based on the integration of UV-HPLC prole and compare it


































































































View Article Onlinereceptor specicity of this imaging agent. These results are
signicant as they are the rst example showing that the 18F-
radiolabelled NHC-BF3 conjugates can image the targeted
tumour in vivo. Clearly, the specic activity is high enough for
tumour imaging application. However, we do like to point out
that the specic activity may need to be improved further for
neuroimaging applications where the receptor number is
limited.Fig. 3 Radio-HPLC profiles of [18F]5 after incubation in phosphate
buffer solution (PBS) pH ¼ 7.5 for 1 hour (A) and 2 hours (B) and radio-
HPLC profiles of [18F]6 and [18F]7 after incubation in PBS pH ¼ 7.5 for 2
hours (C and D).
Fig. 4 Decay corrected microPET/CT images of nude mice from
a static scan at 0.5 h ((A) coronal image, (B) sagittal image) and 4 h ((C)
coronal image, (D) sagittal image) after the injection of [18F]5.
17750 | RSC Adv., 2017, 7, 17748–17751The quantication of the activity accumulation in the major
organs (Fig. 6A and B) was calculated by measuring the regions
of interest (ROIs) encompassing the entire organ. Although the
degrees of tumour uptake of [18F]6 and [18F]7 are different (1.50
 0.013% ID per g for [18F]6 and 0.54 0.031% ID per g for [18F]
7), the tumour-to-muscle ratios of both conjugates areFig. 5 Above: Decay corrected microPET/CT images of nude mice
bearing U87MG tumour from a static scan at 0.5 h after the injection of
[18F]6 ((A) coronal image, (B) transverse image). Below: Decay cor-
rected microPET/CT coronal images of nude mice bearing PANC1
tumour from a static scan at 1 h after the injection of [18F]7 (C) and [18F]
7 co-injected with 200 mg of NT peptide (D) (blocking experiment).
Fig. 6 (A) Bar chart showing microPET quantification of [18F]6 in nude
mice bearing U87MG tumour at 0.5 h post injection. (B) Bar chart
showingmicroPET quantification of [18F]7 in nudemice bearing PANC1
tumour at 1 h post injection.

































































































View Article Onlinecomparable (9.85  0.45 for [18F]6 and 9.33  0.42 for [18F]7)
yielding tumour images with good contrast (Fig. 5A and B for
[18F]6, Fig. 5C for [18F]7). The low liver uptake (0.086  0.0064%
ID per g) and the comparatively high kidney uptake (0.94 0.10)
of [18F]7 at 1 h post injection indicate that [18F]7 rapidly cleared
from liver which is similar to our previous reports on the PET
imaging of 18F-vinyl sulfone conjugated NT-peptide.10
In summary, we have successfully synthesized [18F]-NHC-BF3
conjugated bioactive molecules via SnCl4 promoted
18F–19F
isotopic exchange reaction. This approach allows the uorine-
18 to be introduced at late stage of the synthesis. These
agents showed excellent in vitro and in vivo stability due to the
zwitterionic nature of the NHC-BF3 moiety. As shown in PET
imaging, both RGD and NT conjugates ([18F]6 and [18F]7)
demonstrated prominent tumour uptake with good tumour-to-
background contrast. This approach provides broad applica-
tions for the radiolabelling of thiol-containing bioactive
molecules.
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